Project Grant R01AI198015
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Johns Hopkins University a $672,248 Project Grant on September 15, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a five-year research initiative examining HIV reservoir dynamics and immune responses across the female reproductive lifespan. Led by Co-Principal Investigators Dr. Eileen Scully at Johns Hopkins University and Dr. Ronald Galiwango at...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Johns Hopkins University a $779,616 Project Grant effective April 10, 2026, through March 31, 2031, under the Allergy and Infectious Diseases Research program (CFDA 93.855). This research initiative will characterize the defective human immunodeficiency virus type 1 (HIV-1) proviral reservoir in children and young adults living with perinatal HIV-1 infection. The project will determine the...
- Federal Project Grant Award Summary The Johns Hopkins University received a $1,546,730 Project Grant from the National Institute of Allergy and Infectious Diseases (CFDA 93.855: Allergy and Infectious Diseases Research) awarded June 18, 2025, for continuation and expansion of the Johns Hopkins HIV Implementation Science Hub through May 31, 2030. The Hub serves as a regional consultation entity supporting the Ending the HIV Epidemic (EHE) Initiative by enhancing technical rigor, capacity, and...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Johns Hopkins University a Project Grant of $427,438 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period April 1, 2026 through March 31, 2028. This research initiative focuses on identifying and eliminating antigen-specific expanded clones of latently HIV-infected CD4+ T cells. The project will investigate whether a two-step therapeutic...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Johns Hopkins University a $145,299 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 1, 2025 through July 31, 2029. This award supports the development of novel Bayesian causal structural discovery and reinforcement learning methods to advance precision medicine in HIV care, specifically addressing the challenge of designing...
- Federal Grant Award Summary Fred Hutchinson Cancer Center received a $3.55 million Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) awarded September 12, 2025, with completion targeted for August 31, 2029. This research initiative investigates how oral pre-exposure prophylaxis (PrEP) affects the pharmacokinetics of monoclonal antibodies (MAbs) and vaccine-induced antibodies in women...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Chicago a Project Grant of $126,435 under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective September 16, 2025, through August 31, 2030. The INFOHIV initiative delivers clinical informatics interventions and patient-oriented research designed to optimize HIV prevention and care outcomes. The primary products include the development and...
- Federal Project Grant Award Summary The National Institutes of Health (NIH) Office of the Director awarded The Johns Hopkins University a $428,493 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) on September 5, 2025, for a two-year performance period concluding August 31, 2027. This R21 award supports research characterizing and predicting comorbidity cascades among men and women with and without HIV by integrating data from the MACS/WIHS Combined Cohort Study (MWCCS)...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Johns Hopkins University a $486,470 Project Grant effective August 11, 2025, through July 31, 2027, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports development and validation of direct-from-sample whole genome sequencing (WGS) methods for Neisseria gonorrhoeae that eliminate the need for isolate culturing, thereby reducing technical...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Miami a $1,066,077 Project Grant (CFDA 93.855: Allergy and Infectious Diseases Research) on August 18, 2025, to conduct a hybrid effectiveness-implementation study evaluating PrEP & SOCCER, a multicomponent implementation strategy designed to increase Pre-Exposure Prophylaxis (PrEP) awareness, knowledge, and access among PrEP-eligible men in Miami-Dade, Florida. The...
AWARD SUMMARY The Johns Hopkins University received a $696,200 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective May 12, 2026 through April 30, 2031. The award supports the ON-DEMAND HIV PREVENTION ACROSS THE LIFESPAN: THE OPAL STUDY, a pharmacokinetic/pharmacodynamic research initiative evaluating the efficacy of emtricitabine/tenofovir disoproxil fumarate (F/TDF) pre-exposure prophylaxis (PrEP) in women across reproductive ages. The research will characterize F/TDF concentrations at sites of sexual exposure, including the female genital tract and rectal mucosa, to assess whether event-driven dosing regimens (specifically comparing 2-1-1 versus 2-2-2 dosing schedules) provide adequate HIV prevention protection accounting for reproductive aging-related changes in hormone levels, inflammatory biomarkers, and microbiome composition. The study addresses significant knowledge gaps in HIV prevention by generating critical pharmacologic and immunomodulatory data necessary to optimize on-demand PrEP protocols for women. Deliverables include peer-reviewed research findings, pharmacokinetic/pharmacodynamic characterization data, and evidence-based recommendations regarding the adequacy of different event-driven dosing strategies across the female lifespan, with research to be conducted in Baltimore, Maryland.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $696.2k | 5/12/26 |